Valganciclovir for off-label indications a review of clinical effectiveness
Currently, valganciclovir is not yet indicated for solid organ transplant seropositive recipients, non-solid organ transplantation, such as stem cell transplantation, and other cytomegalovirus (CMV)-related diseases. The aim of this report is to review the clinical effectiveness of valganciclovir fo...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
27 July 2015, 2015
|
| Series: | Rapid response report : summary with critical appraisal
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | Currently, valganciclovir is not yet indicated for solid organ transplant seropositive recipients, non-solid organ transplantation, such as stem cell transplantation, and other cytomegalovirus (CMV)-related diseases. The aim of this report is to review the clinical effectiveness of valganciclovir for off-label indications |
|---|---|
| Physical Description: | 1 PDF file (38 pages) illustration |